Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of leukemia cells in the peripheral blood, bone marrow, and lymphoid tissues. Bruton tyrosine kinase inhibitors (BTKis) are a preferred treatment of patients with CLL. In September 2022, AMCP convened an expert panel of managed care stakeholders to better understand the clinical dynamics of treatment choice in patients with CLL and the key management considerations in CLL with a focus on BTKis.
The Health Disparities Advisory Group is focused on developing resources related to data and formulary and utilization management solutions that can close the gap on disparities in medication use. This advisory group is active from March 2022-February 2023.
The Digital Therapeutics Advisory Group is focused on developing resources for payers on when they should evaluate products, what manufacturers should communicate, and understanding how Digital Therapeutics are included in drug compendia. This advisory group is active from March 2022-February 2023.
The Biosimilars Operational Readiness group is an initiative focused on developing resources to aid in the assessment and implementation of biosimilars when formulary coverage is approved. This group launched in Q4 2022.
Partnership Forum: This forum helped identify payer needs and current barriers that payer currently face regarding evidence for therapies approved through an expedited approval process. In addition, participants identified potential solutions to address evidence gaps.
Partnership Forum: The purpose of the forum was to identify concerns for high-investment medications related to predictability, affordability, and accessibility. Participants also explored alternative payments, financial tools, and policy initiatives related to these medications.
Partnership Forum: This Partnership Forum identified opportunities to improve how value assessments are developed and applied to formulary decision-making and provide strategies and guidance on best practices to equip managed care pharmacists and other professionals when applying these tools to assess value and optimize patient care.